|
|
|
A DNA vaccine can slow disease progression and prolong survival in a mouse model of leukemia, according to a report in the November issue of Nature Medicine.
Rose Ann Padua and coworkers developed a vaccine with pieces of DNA encoding PML-RAR-alpha, a tumor-associated protein, and fragment C of tetanus toxin, a potent immune system stimulant. When injected into a mouse model of acute promyelocytic leukemia (APL), a rare cancer of the white blood cells, the vaccine induced the immune system to make antibodies against the PML-RAR-alpha protein, which is commonly found in APL cancer cells. The vaccine was even more effective at increasing survival when used in combination with all-trans retinoic acid (ATRA), a drug currently used to treat APL. The vaccine-ATRA duo was even more effective than ATRA alone. The researchers suggest the vaccine could eventually be used with ATRA to prolong clinical remission in human patients. Author contact: Rose Ann Padua
King's College Hospital
London, UK
Tel: +44 20 7848 5825
E-mail: RoseAnn.Padua@kingsch.nhs.uk Also available online. (C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|